MyCelx Technologies Corporation Broker Option (5151F)
22 March 2022 - 4:56AM
UK Regulatory
TIDMMYX TIDMMYXR
RNS Number : 5151F
MyCelx Technologies Corporation
21 March 2022
THIS ANNOUNCEMENT, (INCLUDING THE APPENDICES) AND THE TERMS AND
CONDITIONS SET OUT HEREIN (TOGETHER, THIS "ANNOUNCEMENT") AND THE
INFORMATION CONTAINED THEREIN, IS RESTRICTED AND IS NOT FOR
PUBLICATION, RELEASE, DISTRIBUTION OR FORWARDING, DIRECTLY OR
INDIRECTLY, IN WHOLE OR IN PART, TO ANY US PERSONS OR IN OR INTO
THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF
SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION,
RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.
FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND
DOES NOT CONSTITUTE AN OFFER OF SECURITIES IN ANY JURISDICTION.
PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS
ANNOUNCEMENT.
21 March 2022
MYCELX Technologies Corporation
("MYCELX" or the "Company")
Broker Option
MYCELX Technologies Corporation (AIM: MYX), the clean water and
clean air technology company, is pleased to announce that further
to the announcement of the Proposed Placing and Subscription on 11
March 2022, the Broker Option has been exercised in respect of
155,000 new Common Shares (the "Broker Option Shares"), raising
additional gross proceeds of $101,500 (c GBP77,500) for the
Company.
The Broker Option Shares will be issued at a price of 50 pence
per new Common Share (being the Issue Price) and on the same terms
and conditions as the Placing, including the fact that they are to
be issued into the new restricted line of Common Shares under the
symbol MYXR.
With the exercise of the Broker Option and the admission of the
Placing and Subscription to trading on AIM, this results in a total
gross fundraise of $2.31million (c.GBP1.77 million*) for the
Company; comprising the Placing and Subscription raising c.$2.21
million (c.GBP1.69 million*) (before expenses), and the Broker
Option raising $101,500 (c.GBP77,500*).
Admission and dealings
Application will be made to the London Stock Exchange for the
155,000 Broker Option Shares to be admitted to trading on AIM (the
"Further Admission"). Admission of the Placing and Subscription
became effective on 21 March 2022 , the Broker Option Shares are
expected to become effective and dealings commence at 8.00 a.m. on
or around 25 March 2022.
The new Common Shares to be issued in connection with the
Placing and Subscription and the Broker Option, when issued, rank
pari passu with the existing Common Shares, including the right to
receive future dividends.
Upon the Further Admission, the new Common Shares issued
pursuant to the Broker Option will also trade in the Company's new
restricted line of Common Shares under the symbol MYXR, and the new
Common Shares, as represented by depositary interests ("Depository
Interests"), will be held in the CREST system and will be
segregated into a separate trading system within CREST identified
with the marker "REG S" and USU624551235.
Total Voting Rights
Following the Further Admission, and as a result of the Broker
Option being partially exercised, the total number of Common Shares
in the Company with voting rights is expected to be 22,983,023.
Terms and definitions used in this announcement shall have the
same meaning as ascribed to them in the Company's announcements
dated 11 March 2022 regarding the Proposed Placing and Subscription
unless otherwise stated.
*Exchange rate of GBP: USD 1.31
further information, please contact:
MYCELX Technologies Corporation
Connie Mixon, Chief Executive Officer +1 770 534 3118
Kim Slayton, Chief Financial Officer
Canaccord Genuity Limited (NOMAD, Broker and
Bookrunner)
Henry Fitzgerald-O'Connor
Gordon Hamilton
Sam Lucas (ECM) +44 207 523 8000
Celicourt Communications (Financial PR)
Mark Antelme +44 208 434 2643
Jimmy Lea
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
FURUASBRUWUOUAR
(END) Dow Jones Newswires
March 21, 2022 13:56 ET (17:56 GMT)
Mycelx Technologies (LSE:MYX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mycelx Technologies (LSE:MYX)
Historical Stock Chart
From Jul 2023 to Jul 2024